Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are two of the commonest causes of transverse myelitis, a syndrome with multiple causes. NMOSD attacks commonly result in permanent blindness or paraplegia and do so much more frequently than MS attacks, so early accurate diagnosis is critical. 1 Furthermore, misdiagnosis of NMOSD as MS and institution of MS-targeted attack prevention medications may be ineffective (glatiramer acetate) 2 or worsen NMOSD (beta-interferon, natalizumab, fingolimod, and alemtuzumab). 3, 4 Prior to 2004, a longitudinally extensive intramedullary T2-hyperintense lesion extending three or more vertebral segments on sagittal magnetic resonance imaging (MRI) spine (longitudinally extensive transverse myelitis, LETM) was the best discriminator of NMOSD from MS, 1 except perhaps for children. 5 However, the rule of a three-vertebral segment lesion indicating NMOSD is overly simple and there are many exceptions. There are other causes of longitudinally extensive spinal cord lesions including sarcoidosis, dural arteriovenous fistula, or spinal cord infarction. 6 Furthermore, coalescence of multiple short chronic T2 MS lesions may be confused for LETM on sagittal images; axial images may demonstrate that such lesions consist of multiple discrete adjacent T2-hyperintense lesions concentrated in the peripheral spinal cord and this finding favors MS rather than NMOSD. Vertebral length varies from cervical through thoracic spine and may differ from patient to patient or may change as a result of an acquired disorder (e.g. vertebral compression fractures). "Borderline" myelitis lesions that span 2.5-3.5 vertebral segments are potentially problematic, as discussed below. Timing of the MRI may also influence lesion length; a short lesion detected within the first 24 hours could evolve into a long lesion a day or two later. 7 Alternatively, imaging too late may result in detection of a discontinuous lesion or a lesion may resolve completely. 8 Despite these pitfalls, this radiologic finding has proved clinically useful and LETM is recognized by most neurologists as an indication for aquaporin-4-IgG testing. On the contrary, short transverse myelitis (STM), which occurs most commonly as a manifestation or precursor of MS, may lead one to overlook the possibility of NMOSD and discount the need for aquaporin-4-IgG testing.
In this issue of the journal, Huh et al. 9 assessed the frequency and characteristics of STM in Korean patients with aquaporin-4-IgG seropositive NMOSD. They focused on patients in whom myelitis was the presenting manifestation of NMOSD when diagnostic uncertainty is greatest. In all, 14.5% of initial NMOSD myelitis episodes were accompanied by STM, similar to the frequency in a previous report (14%) 10 and higher than reported in a previous study that included AQP4-IgG seronegative cases (7.3%). 11 Huh et al. 9 found that STM in NMOSD were centrally located rather than peripherally located on axial images, as is typical of MS-associated STM lesions which are usually in dorsal or lateral columns. Most NMOSDassociated STM in this study extended over two vertebral segments on sagittal images, whereas MS-associated STM typically span less than two vertebral segments. (This study lacked a control group of MS patients.) Diagnosis and treatment were frequently delayed when the initial presentation of NMOSD was an STM and some patients were treated with interferon-β for MS with its attendant potential to worsen NMOSD. 3 Patients not recognized to have NMOSD at the time of the initial STM episode had greater disability at last follow-up.
Selection of patients in whom aquaporin-4-IgG (AQP4-IgG) testing is appropriate is problematic. In the correct setting, AQP4-IgG is highly specific, but in patients with low pre-test probability, the test is false positive more commonly than true positive particularly with older generation non-cell-based assays (e.g. enzyme-linked immunosorbent assay (ELISA)) in which the risk of false positives is fivefold higher than with newer generation cell-based techniques. 12 The authors of this study highlight a number of nonradiological characteristics that may help select those patients with STM in whom aquaporin-4-IgG testing is indicated. As Huh et al. 9 point out, the prevalence of MS is relatively low in Korean and other Asian populations or in regions close to the equator; therefore, the pre-test probability of STM being a manifestation of NMOSD is higher in Asian than in western countries where the prevalence of MS exceeds that of NMOSD by 50-fold. 9 Other radiological features also increase the pre-test probability of NMOSD over MS: central location of STM on axial images; dearth of characteristic MS brain MRI lesions or presence of NMOSD-typical brain lesions surrounding the third and fourth ventricles; coexisting autoimmune disorders (systemic lupus erythematosus, Sjogren's syndrome, or myasthenia gravis); a history of unexplained nausea/vomiting or hiccups; and absence of cerebrospinal fluid (CSF) oligoclonal bands.
Huh et al. 9 have confirmed that STM can be the first manifestation of NMOSD; AQP4-IgG testing is indicated for lesions that are on the borderline of the three-vertebral segment cutoff rule that defines STM and LETM. Failure to recognize STM as a potential manifestation of NMOSD carries significant risk. And that is the long and the short of it.
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